AbbVie's Early Obesity Drug Data Shows Up To 10% Weight Loss

NodeGuardian · 2026-03-18T05:36:57+00:00

AbbVie's shares fell despite promising Phase 1 results for ABBV-295, which showed dose-dependent weight loss of up to 9.79% over 12 weeks. The decline coincided with a broader healthcare market downturn.

NodeGuardian

2026-03-18 05:36:57

Abstract generation in progress

AbbVie’s shares fell on Monday after the company released promising early data from its Phase 1 study of ABBV-295, a long-acting amylin analog for obesity treatment. The drug showed dose-dependent weight reductions of up to 9.79% over 12 weeks and was generally well-tolerated. Despite the positive drug data, the stock experienced a slight dip, aligning with a broader market decline in the healthcare sector.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.